Vertex Sells Legacy Oncology Portfolio To German Merck
Executive Summary
Vertex Pharmaceuticals has sold off its oncology portfolio, comprised of six molecules across four early stage programs, to Merck of Germany for $230m and future royalties on sales – a low price tag in the immune-oncology deal spree arena.